Trials / Completed
CompletedNCT06380881
PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases
A Single-center, Open-label, Single-arm Phase Ib Clinical Study to Evaluate the Pharmacokinetics and Pharmacodynamic Characteristics of SHR-2017 Injection in Patients With Bone Metastases
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2017 | SHR-2017 |
Timeline
- Start date
- 2024-05-20
- Primary completion
- 2025-08-06
- Completion
- 2025-08-06
- First posted
- 2024-04-24
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06380881. Inclusion in this directory is not an endorsement.